Validation of the United Kingdom copy-number alteration classifier in 3239 children with B-cell precursor ALL.
Adolescent
Biomarkers, Tumor
Child
Child, Preschool
Cytogenetic Analysis
DNA Copy Number Variations
Female
Follow-Up Studies
Genetic Association Studies
Genetic Predisposition to Disease
Humans
Infant
Male
Patient Outcome Assessment
Population Surveillance
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
/ diagnosis
Prognosis
Proportional Hazards Models
United Kingdom
/ epidemiology
Young Adult
Journal
Blood advances
ISSN: 2473-9537
Titre abrégé: Blood Adv
Pays: United States
ID NLM: 101698425
Informations de publication
Date de publication:
22 01 2019
22 01 2019
Historique:
received:
05
09
2018
accepted:
06
12
2018
entrez:
18
1
2019
pubmed:
18
1
2019
medline:
10
1
2020
Statut:
ppublish
Résumé
Genetic abnormalities provide vital diagnostic and prognostic information in pediatric acute lymphoblastic leukemia (ALL) and are increasingly used to assign patients to risk groups. We recently proposed a novel classifier based on the copy-number alteration (CNA) profile of the 8 most commonly deleted genes in B-cell precursor ALL. This classifier defined 3 CNA subgroups in consecutive UK trials and was able to discriminate patients with intermediate-risk cytogenetics. In this study, we sought to validate the United Kingdom ALL (UKALL)-CNA classifier and reevaluate the interaction with cytogenetic risk groups using individual patient data from 3239 cases collected from 12 groups within the International BFM Study Group. The classifier was validated and defined 3 risk groups with distinct event-free survival (EFS) rates: good (88%), intermediate (76%), and poor (68%) (
Identifiants
pubmed: 30651283
pii: bloodadvances.2018025718
doi: 10.1182/bloodadvances.2018025718
pmc: PMC6341196
doi:
Substances chimiques
Biomarkers, Tumor
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
148-157Subventions
Organisme : Blood Cancer UK
ID : 10060
Pays : United Kingdom
Organisme : Blood Cancer UK
ID : 12026
Pays : United Kingdom
Organisme : Blood Cancer UK
ID : 15014
Pays : United Kingdom
Informations de copyright
© 2019 by The American Society of Hematology.
Références
Lancet Oncol. 2010 May;11(5):429-38
pubmed: 20409752
Lancet Oncol. 2014 Jul;15(8):809-18
pubmed: 24924991
Lancet Haematol. 2017 May;4(5):e202-e217
pubmed: 28411119
J Clin Oncol. 2018 Apr 20;36(12):1240-1249
pubmed: 29498923
Leukemia. 2013 Jul;27(7):1497-503
pubmed: 23407458
Blood. 2010 Jul 1;115(26):5393-7
pubmed: 20378752
Nature. 2007 Apr 12;446(7137):758-64
pubmed: 17344859
Leukemia. 2012 Oct;26(10):2245-53
pubmed: 22484421
J Clin Oncol. 2015 Sep 20;33(27):2938-48
pubmed: 26304874
Blood. 2013 Oct 10;122(15):2622-9
pubmed: 23974192
Leukemia. 2014 Jan;28(1):70-7
pubmed: 24064621
Br J Haematol. 2018 Feb;180(4):550-562
pubmed: 29194562
Leukemia. 2007 Jun;21(6):1258-66
pubmed: 17443227
Haematologica. 2017 Mar;102(3):541-551
pubmed: 27979924
Lancet Oncol. 2013 Mar;14(3):199-209
pubmed: 23395119
Blood. 2014 Aug 28;124(9):1434-44
pubmed: 24957142
Stat Med. 2002 Jun 15;21(11):1539-58
pubmed: 12111919
J Clin Oncol. 2018 Jan 1;36(1):34-43
pubmed: 29131699
Leukemia. 2015 Nov;29(11):2154-61
pubmed: 26050650
Blood Rev. 2012 May;26(3):123-35
pubmed: 22436535
Blood Adv. 2017 Aug 14;1(19):1473-1477
pubmed: 29296789
J Clin Oncol. 2014 Sep 20;32(27):3012-20
pubmed: 25049327
Leukemia. 2010 Jul;24(7):1258-64
pubmed: 20445578
Haematologica. 2013 Mar;98(3):428-32
pubmed: 22875627